Valuation: NovoCure Limited

Market Cap 1.74B 1.55B 1.44B 1.31B 2.48B 167B 2.5B 17.46B 6.77B 85.5B 6.53B 6.39B 274B P/E 2026 *
-11.9x
P/E 2027 * -18.3x
Enterprise Value 1.63B 1.45B 1.36B 1.24B 2.33B 157B 2.35B 16.4B 6.36B 80.31B 6.14B 6B 258B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 1.9x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day-6.16%
1 week-5.68%
Current month-6.33%
1 month-16.21%
3 months-13.14%
6 months+41.61%
Current year+15.55%
1 week 14.92
Extreme 14.915
16.44
1 month 14.92
Extreme 14.915
18.02
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
124.35
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Director/Board Member 59 01/01/2012
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
30/6/26 Free

Chief Executive Officer

1,905 0.0016%
30/6/26 Free

Head of Human Resources

1,905 0.0016%
30/6/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-5.68%+6.33%-4.17% 1.74B
+0.84%-3.74%-26.69%+1.85% 169B
-0.07%-2.55%-9.53%+11.07% 110B
+0.90%+1.13%-24.83%+0.58% 106B
-1.24%-0.76%-49.04%-12.75% 73.87B
-0.24%+0.69%+0.16%+72.58% 58.98B
-0.86%+2.96%+13.57%+59.50% 51.28B
-0.71%-3.82%-7.72%-31.41% 48.16B
+0.12%-0.17%-18.21%+20.29% 40.84B
-1.01%-1.45%+28.48%-9.72% 32.21B
Average -0.84%-1.34%-8.75%+10.78% 69.19B
Weighted average by Cap. +0.01%-1.31%-16.31%+10.09%

Financials

2026 *2027 *
Net sales 726M 645M 602M 549M 1.03B 69.78B 1.04B 7.28B 2.82B 35.67B 2.73B 2.67B 114B 805M 715M 667M 608M 1.15B 77.37B 1.16B 8.08B 3.13B 39.55B 3.02B 2.96B 127B
Net income -142M -126M -118M -107M -202M -13.65B -204M -1.43B -552M -6.98B -533M -522M -22.4B -84.78M -75.33M -70.31M -64.08M -121M -8.15B -122M -851M -330M -4.17B -318M -311M -13.37B
Net Debt -105M -93.72M -87.47M -79.73M -150M -10.14B -152M -1.06B -410M -5.18B -396M -387M -16.64B -210M -187M -174M -159M -299M -20.18B -302M -2.11B -816M -10.32B -788M -771M -33.11B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
02/10/26 USD 14.94 -6.16% 1,695,114
01/10/26 USD 15.92 -0.19% 1,208,080
30/09/26 USD 15.95 -0.25% 1,876,602
29/09/26 USD 15.99 +1.01% 728,540
28/09/26 USD 15.83 -0.06% 895,992
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
14.94USD
Average target price
27.14USD
Spread / Average Target
+81.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock